The Business Research Company’s report on the Dyslipidemia Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the dyslipidemia market’s growth in recent years?
The increasing obese population is expected to propel the growth of the dyslipidemia market going forward. The obese population refers to individuals who have excess body fat that may negatively impact their health. The obese population is increasing as lifestyle shifts cause prolonged energy imbalances, resulting in gradual weight gain and related health issues. Obesity causes dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels that increase the risk of cardiovascular diseases. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately one in eight people worldwide struggle with obesity, including 2.5 billion adults aged 18 and older. Additionally, the number of overweight children under five years old reached 37 million. Therefore, the increasing obese population drives the dyslipidemia market.
Access Your Free Sample of the Global Dyslipidemia Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21945&type=smp
How does the future projection of the dyslipidemia market size compare to its historical growth?
The dyslipidemia market size has grown rapidly in recent years. It will grow from $16.31 billion in 2024 to $18.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising genetic predisposition, increasing sedentary lifestyle, rising unhealthy diet, growing aging population, and increasing obesity rates.
The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing advancements in lipid-lowering therapies, growing awareness and screening programs, rising prevalence of metabolic disorders, increasing healthcare expenditure, and rising prevalence of dyslipidemia. Major trends in the forecast period include advancement in gene therapies, innovation in RNA-based treatments, advancement in AI-driven drug discovery, advancement in personalized medicine, and innovation in digital health monitoring.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21945&type=smp
Which key players are shaping the future of the dyslipidemia market?
Major companies operating in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical
What trends will propel the growth and evolution of the dyslipidemia market?
Major companies operating in the dyslipidemia market are focusing on developing advanced combination therapies to enhance treatment efficacy, improve patient compliance, and address multiple lipid abnormalities simultaneously. Advanced combination therapies refer to treatment approaches that use two or more therapeutic agents in a single regimen to improve efficacy, reduce side effects, and target multiple disease mechanisms simultaneously. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company announced NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) approved by the Food and Drug Administration, a US-based government agency. These advanced non-statin oral medications are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The new labels allow for the use of NEXLETOL and NEXLIZET either alone or in combination with statins, which are commonly used cholesterol-lowering drugs. This flexibility is particularly beneficial for patients who cannot tolerate statins or prefer non-statin options.
Which regions are expected to become dominant players in the dyslipidemia market?
North America was the largest region in the dyslipidemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyslipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/dyslipidemia-global-market-report
What are the emerging key segments in the dyslipidemia market, and how are they evolving?
The dyslipidemia market covered in this report is segmented –
1) By Treatment: Statins, Bile Acid Sequestrants, PCSK9 Inhibitors, Small Interfering RNA (siRNA), Cholesterol Absorption Inhibitors, Fibrates, Niacins, Omega-3 Fatty Acid Derivatives, Other Treatments
2) By Route Of Administration: Oral, Parental
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Store, Online Pharmacies
Subsegments:
1) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin
2) By Bile Acid Sequestrants: Cholestyramine, Colesevelam
3) By PCSK9 Inhibitors: Evolocumab, Alirocumab
4) By Small Interfering RNA (siRNA): Inclisiran
5) By Cholesterol Absorption Inhibitors: Ezetimibe
6) By Fibrates: Fenofibrate, Gemfibrozil
7) By Niacins: Nicotinic Acid
8) By Omega-3 Fatty Acid Derivatives: Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)
9) By Other Treatments: Herbal Supplements, Combination Therapies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21945
How is the dyslipidemia market defined?
Dyslipidemia is a health condition where the levels of lipids (fats) in the blood become abnormal. Managing dyslipidemia primarily aims to regulate lipid levels, reduce the risk of cardiovascular diseases, and improve heart health through a combination of lifestyle modifications, medication, and routine monitoring.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
